MedPath

Shockless Implant Evaluation

Not Applicable
Completed
Conditions
Ventricular Tachycardia
Ventricular Fibrillation
Interventions
Device: Implantable defibrillator
Registration Number
NCT00800384
Lead Sponsor
Boston Scientific Corporation
Brief Summary

This trial will assess the safety of defibrillator testing and the influence of defibrillation testing on the efficacy of clinical shocks.

The trial will test the hypothesis that implantable cardioverter defibrillator (ICD) implantation without defibrillation testing (DT) is non-inferior to implantation with testing against the composite endpoint of ineffective first appropriate clinical shock or arrhythmic death.

It will also test the hypothesis, that defibrillation testing increases the peri-operative (30 days) complication rate of ICD implantation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2500
Inclusion Criteria
  • Age ≥ 18 years
  • Patients undergoing initial implant of an ICD or CRT-D device (can be upgrade from a pacemaker)
Exclusion Criteria
  • Patients, who in the opinion of their treating physicians are ineligible for either strategy (DT or no DT)
  • Patients on active transplant list
  • Patients unwilling to provide informed consent
  • Patients not available for follow-up
  • Pregnancy or women of child bearing potential not following an effective method of contraception
  • Anticipated right sided implantation of the ICD generator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Implantable defibrillatorICD implant with defibrillation testing
1Implantable defibrillatorICD implant without defibrillation testing
Primary Outcome Measures
NameTimeMethod
First Occurrence of the Composite of Failed First Appropriate Clinical Shock From the Implantable Cardioverter Defibrillator (ICD) or Arrhythmic DeathMean follow-up of 3.1 years

The number of patients having experienced either an appropriate inefficient shock and/or arrhythmic death during the follow-up time frame of 3.1 years is compared between both groups.

Secondary Outcome Measures
NameTimeMethod
Perioperative Complication Rate30 days

A predefined set of expected complications attributed to defibrillation testing during implant procedure was analyzed in both groups.

Trial Locations

Locations (85)

The Royal Melbourne Hospital

🇦🇺

Melbourne, Australia

Landesklinikum St. Poelten

🇦🇹

St. Poelten, Austria

Allgemeines Krankenhaus Wien

🇦🇹

Vienna, Austria

Wilhelminenspital

🇦🇹

Vienna, Austria

Klinikum Wels - Grieskirchen

🇦🇹

Wels, Austria

University of Alberta Hospital

🇨🇦

Edmonton, Alberta, Canada

Royal Jubilee Hospital

🇨🇦

Victoria, British Columbia, Canada

St. Boniface General Hospital

🇨🇦

Winnipeg, Manitoba, Canada

Queen Elizabeth II Health Sciences Center

🇨🇦

Halifax, Nova Scotia, Canada

Hamilton General Hospital

🇨🇦

Hamilton, Ontario, Canada

Scroll for more (75 remaining)
The Royal Melbourne Hospital
🇦🇺Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath